Read about our COVID-19 Response. Insights: A Leadership Blog Newsroom Webinars and Podcasts Insights: Blog The Lifeblood of Preparedness Lindsay Peters, Health Policy Intern, Cerus Corporation October 2021 We are living in an era of pandemics. With each passing year, the threat lives on, as more emerging pathogens are identified and impact human lives. Innovations that are available today and in the pipeline for tomorrow must be leveraged to help secure the safety and sustainability of our blood supply. Supporting the continuity of hospital care and ensuring all patients have access to life-saving blood transfusions must be made integral to pandemic preparedness across the globe. READ MORE Highlights from the Annual AABB 2020 Virtual Meeting Vera Chrebtow, Senior Director, Global Marketing December 2020 Even during a global pandemic, one of the most rewarding experiences within the global transfusion community is the opportunity to gather and share findings with colleagues, peers, and friends. This fall, representatives from Cerus were excited to present data from 17 abstracts at the Annual AABB 2020 Virtual Meeting. READ MORE Are You Ready to Meet the FDA's Platelet Safety Guidance Deadline? Vivek K. Jayaraman, Chief Operating Officer October 2020 Likely not since World War II have the topics of blood and blood components had greater awareness in our public discourse. Lately, our news feeds are saturated with hematology-centric headlines reminding the general public that the safety and availability of blood are essential. This is, of course, a world that our community lives and breathes every day. READ MORE Team Work and Communications in the Age of Covid Lori L. Roll, Vice President of Administration September 2020 With oversight of the company’s human resources, facilities and recruiting as well as a member of the Cerus COVID-19 task force, hear from our Vice President of Administration, Lori Roll, who covers the importance of collaboration while leading during a pandemic and the company’s long history growing diverse teams. READ MORE Maximizing the Clinical Impact of Platelet Donations in Extraordinary Times Richard J. Benjamin MD Ph.D. FRCPath August 2020 Extraordinary times call for measures that may not be so extraordinary after all. The INTERCEPT Blood System for Platelets, which has already been implemented in Belgium, France, and Switzerland, could be used universally across the U.S. healthcare system to safeguard the blood supply and broaden the donor pool at a time when we are at risk of blood shortages nationally. Cerus chief medical officer Dr. Richard Benjamin writes about the issue of pandemic blood shortages in his latest blog post. READ MORE A Brief History of Blood Safety and Pathogen Reduction Technology Laurence M Corash, M.D. July 2020 Part one of a series. Dr. Laurence Corash, chief scientific officer at Cerus, shares his perspective on blood safety and how it has evolved over the last 40 years. He served as chief of the Clinical Hematology Laboratory Service for the Medical Center at the University of California, San Francisco (UCSF) starting in the early 1980s and witnessed, firsthand, the toll and impact that AIDS had on blood transfusion safety in the United States and around the world. Corash explores the history and technological innovation that has been influential in increasing the safety and effectiveness of the world’s blood supply. READ MORE Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2020 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.1.0 About Cerus About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK